Fatigue is listed as a common adverse reaction in FDA prescribing information, occurring in 5% or more of patients taking Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide), with higher frequency than placebo in clinical trials
Around one in 10 Americans now take GLP-1 drugs: and this figure is only set to rise
2 capsules once daily
In summary, this effect may be the cause or a consequence of the beneficial effects of BPC 157 on related disturbances [1,2,3,4,5,6,7,8,9,10,11]
As a freeze-dried powder in a single sealed vial, despatched same-day from the UK with Royal Mail Tracked 24
Tolkachjov, MD, FAAD, FACMS, can be reached at [email protected]